Aerska
Aerska Launches with $21M to Use Brain ‘Shuttles’ for RNAi Delivery in Neurological Diseases
Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates